Monoclonal Gammopathy for Unique Populations
(MAGIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the prevalence of monoclonal gammopathy in individuals of East African descent. Monoclonal gammopathy involves abnormal proteins in the blood and can sometimes progress to more serious conditions like multiple myeloma. Researchers seek to better understand how this condition affects the East African community to improve treatment and prevention strategies. Individuals with East African ancestry who are 40 years or older may be suitable for this study. Participants will have their medical history reviewed, provide a blood sample, and complete a questionnaire.
As an unphased study, this trial offers participants the chance to contribute to significant research that could enhance health outcomes for their community.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to understand the prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM) specifically among unique populations of Black people. Unlike standard treatment options that focus on managing these conditions, this trial is observational and seeks to identify how often MGUS and MM occur, potentially leading to earlier detection and better-targeted treatments in the future. By focusing on medical chart reviews and blood sample analysis, this study could reveal critical insights into racial disparities in these diseases, ultimately contributing to more personalized and effective healthcare solutions.
Who Is on the Research Team?
Joselle M. Cook, M.B.B.S.
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observational
Participants undergo medical chart review, blood sample collection, and complete a questionnaire. Those who test positive for MGUS are notified along with their primary care physician.
Follow-up
Participants who test positive for MGUS receive necessary follow-up and referral as clinically indicated.
What Are the Treatments Tested in This Trial?
Interventions
- Non-Interventional Study
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.